Logo image of VTVT

VTV THERAPEUTICS INC- CL A (VTVT) Stock Fundamental Analysis

NASDAQ:VTVT - Nasdaq - US9183852048 - Common Stock - Currency: USD

17.76  -1.69 (-8.69%)

Fundamental Rating

3

Overall VTVT gets a fundamental rating of 3 out of 10. We evaluated VTVT against 562 industry peers in the Biotechnology industry. While VTVT has a great health rating, there are worries on its profitability. VTVT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VTVT has reported negative net income.
VTVT had a negative operating cash flow in the past year.
VTVT had negative earnings in each of the past 5 years.
VTVT had a negative operating cash flow in each of the past 5 years.
VTVT Yearly Net Income VS EBIT VS OCF VS FCFVTVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

VTVT has a Return On Assets (-48.25%) which is comparable to the rest of the industry.
The Return On Equity of VTVT (-151.34%) is worse than 63.46% of its industry peers.
Industry RankSector Rank
ROA -48.25%
ROE -151.34%
ROIC N/A
ROA(3y)-96.56%
ROA(5y)-79.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VTVT Yearly ROA, ROE, ROICVTVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VTVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTVT Yearly Profit, Operating, Gross MarginsVTVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

VTVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
VTVT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VTVT has been reduced compared to 5 years ago.
There is no outstanding debt for VTVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VTVT Yearly Shares OutstandingVTVT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VTVT Yearly Total Debt VS Total AssetsVTVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -10.56, we must say that VTVT is in the distress zone and has some risk of bankruptcy.
VTVT has a worse Altman-Z score (-10.56) than 75.76% of its industry peers.
There is no outstanding debt for VTVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.56
ROIC/WACCN/A
WACC10.01%
VTVT Yearly LT Debt VS Equity VS FCFVTVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

2.3 Liquidity

A Current Ratio of 7.34 indicates that VTVT has no problem at all paying its short term obligations.
The Current ratio of VTVT (7.34) is better than 69.88% of its industry peers.
VTVT has a Quick Ratio of 7.34. This indicates that VTVT is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.34, VTVT is doing good in the industry, outperforming 70.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.34
Quick Ratio 7.34
VTVT Yearly Current Assets VS Current LiabilitesVTVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for VTVT have decreased strongly by -1963.64% in the last year.
VTVT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -49.63%.
The Revenue has been growing by 47.43% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1963.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.66%
Revenue 1Y (TTM)-49.63%
Revenue growth 3Y-9.88%
Revenue growth 5Y47.43%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VTVT will show a small growth in Earnings Per Share. The EPS will grow by 0.47% on average per year.
VTVT is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y91.69%
EPS Next 2Y8.63%
EPS Next 3Y2.85%
EPS Next 5Y0.47%
Revenue Next Year-100%
Revenue Next 2Y-29.39%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VTVT Yearly Revenue VS EstimatesVTVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2028 2029 2030 20M 40M 60M 80M
VTVT Yearly EPS VS EstimatesVTVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VTVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VTVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTVT Price Earnings VS Forward Price EarningsVTVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTVT Per share dataVTVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.63%
EPS Next 3Y2.85%

More info and screens

0

5. Dividend

5.1 Amount

VTVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VTV THERAPEUTICS INC- CL A

NASDAQ:VTVT (5/23/2025, 9:02:50 PM)

17.76

-1.69 (-8.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-06 2025-08-06
Inst Owners22.89%
Inst Owner Change3.68%
Ins Owners1.5%
Ins Owner Change0%
Market Cap56.65M
Analysts82.5
Price Target36.21 (103.89%)
Short Float %1.28%
Short Ratio0.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.43%
PT rev (3m)1.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)25.91%
EPS NY rev (1m)0%
EPS NY rev (3m)16.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 55.71
P/FCF N/A
P/OCF N/A
P/B 4.64
P/tB 4.64
EV/EBITDA N/A
EPS(TTM)-4.54
EYN/A
EPS(NY)-3.72
Fwd EYN/A
FCF(TTM)-7.93
FCFYN/A
OCF(TTM)-7.93
OCFYN/A
SpS0.32
BVpS3.82
TBVpS3.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.25%
ROE -151.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-96.56%
ROA(5y)-79.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.34
Quick Ratio 7.34
Altman-Z -10.56
F-Score5
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)7.41%
Cap/Depr(5y)4.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1963.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.66%
EPS Next Y91.69%
EPS Next 2Y8.63%
EPS Next 3Y2.85%
EPS Next 5Y0.47%
Revenue 1Y (TTM)-49.63%
Revenue growth 3Y-9.88%
Revenue growth 5Y47.43%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-29.39%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y5.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.63%
OCF growth 3YN/A
OCF growth 5YN/A